{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:35Z","timestamp":1791417635043,"version":"4.3.3"},"reference-count":68,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/13696998.2025.2558450","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T07:40:02Z","timestamp":1758008402000},"page":"1639-1650","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Budget impact of introducing an omalizumab biosimilar in 23 European countries"],"prefix":"10.1080","volume":"28","author":[{"given":"Minyoung","family":"Jang","sequence":"first","affiliation":[{"name":"Celltrion, Inc","place":["Incheon, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jooyeop","family":"Lee","sequence":"additional","affiliation":[{"name":"Celltrion, Inc","place":["Incheon, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungjae","family":"Yi","sequence":"additional","affiliation":[{"name":"Celltrion, Inc","place":["Incheon, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taek Sang","family":"Kwon","sequence":"additional","affiliation":[{"name":"Celltrion, Inc","place":["Incheon, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"e_1_3_5_2_1","unstructured":"Xolair | European Medicines Agency (EMA). [Internet]. 2018. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xolair"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2008.01723.x"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S12494"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00288"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.625296"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18136952"},{"key":"e_1_3_5_8_1","unstructured":"Abbate J. Who wants the biggest slice of the biosimilar pie?. The Humira biosimilar wave in Europe | EVERSANA. 2019. https:\/\/www.eversana.com\/zh\/insights\/who-wants-the-biggest-slice-of-the-biosimilar-pie-the-humira-biosimilar-wave-in-europe\/"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.10.053"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.05.019"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/jvc2.324"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2016.04.012"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.3205\/cto000126"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2024.03.036"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40413-017-0159-y"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.03.002"},{"key":"e_1_3_5_17_1","unstructured":"Omlyclo | European Medicines Agency (EMA). 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/omlyclo."},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.07.045"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12020165"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01040-9"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.2147\/RMHP.S211321"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.02.017"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.02.017"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.23750\/abm.v92iS7.12415"},{"key":"e_1_3_5_25_1","unstructured":"xolair-epar-product-information_en.pdf. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xolair-epar-product-information_en.pdf"},{"key":"e_1_3_5_26_1","unstructured":"Jang M. Biosimilars: the Key to Lowering Access Barriers to Omalizumab Across Europe [Internet]. 2024. https:\/\/www.ispor.org\/docs\/default-source\/euro2024\/isporeurope24yihpr41poster143982-pdf.pdf?sfvrsn=56c1cffb_0"},{"key":"e_1_3_5_27_1","unstructured":"Objavljene liste lijekova | HZZO. 2025. http:\/\/hzzo.hr\/poslovni-subjekti\/zdravstvena-zastita\/lijekovi\/objavljene-liste-lijekova."},{"key":"e_1_3_5_28_1","unstructured":"S\u00daKL - P\u0159ehled l\u00e9\u010div. S\u00daKL - P\u0159ehled l\u00e9\u010div. 2025. https:\/\/prehledy.sukl.cz\/prehled_leciv.html#\/leciva\/0149028."},{"key":"e_1_3_5_29_1","unstructured":"Hansanet D Andmevara L H PK. Tervisekassa tervishoiuteenuste loetelu | ESTLEX [Internet]. 2025. https:\/\/estlex.ee\/akt\/240306."},{"key":"e_1_3_5_30_1","unstructured":"344 Omalitsumabi. Kela. 2025. https:\/\/www.kela.fi\/laake344"},{"key":"e_1_3_5_31_1","unstructured":"Medicine - Common Catalogue. 2025. https:\/\/www.felleskatalogen.no\/medisin\/internsok?sokord=xolair"},{"key":"e_1_3_5_32_1","unstructured":"S\u00f6k priser och beslut i databasen. Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket TLV [Internet]. 2025. https:\/\/www.tlv.se\/beslut\/sok-priser-och-beslut-i-databasen.html."},{"key":"e_1_3_5_33_1","unstructured":"Teknoloji O. Kayseri Eczac\u0131 Odas\u0131. 2025. https:\/\/www.kayserieo.org.tr\/duyuru\/omalizumabxolair-etken-maddeli-ilacta-yapilan-kesintiler-hk-1969?"},{"key":"e_1_3_5_34_1","unstructured":"Ministry of Health of the Slovak Republic. Notice of the initiation of proceedings on the initiative of the Ministry. Ministry of Health of the Slovak Republic; Report No.: 363\/. 2011."},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389203717666160226144618"},{"key":"e_1_3_5_36_1","unstructured":"Celltrion \uc140\ud2b8\ub9ac\uc628. \uc140\ud2b8\ub9ac\uc628 Celltrion. 2025. https:\/\/www.celltrion.com\/en-us\/company\/media-center\/press-release\/3125"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.16446"},{"key":"e_1_3_5_38_1","unstructured":"Biosimilars Often Reduce Prices by 50 Percent or More. Pacific Research Institute [Internet]. 2025. https:\/\/www.pacificresearch.org\/biosimilars-often-reduce-prices-by-50-percent-or-more\/."},{"key":"e_1_3_5_39_1","unstructured":"IQVIA Analytics. 2025. https:\/\/analyticslink.customerportal.iqvia.com\/."},{"key":"e_1_3_5_40_1","unstructured":"Average Weight for Men: Age Height Body Composition & More. 2025. https:\/\/www.healthline.com\/health\/mens-health\/average-weight-for-men#average-weight-around-the-world"},{"key":"e_1_3_5_41_1","unstructured":"SMART. \u2013 Global MIDAS Edition. 2025. https:\/\/smartmidas.imshealth.com\/ui\/default.aspx."},{"key":"e_1_3_5_42_1","unstructured":"APOVERLAG. | Product catalog. 2025. https:\/\/warenverzeichnis.apoverlag.at\/."},{"key":"e_1_3_5_43_1","unstructured":"Zoekmodules SSP - bijgewerkt op. 2025. https:\/\/webappsa.riziv-inami.fgov.be\/ssp\/ProductSearch."},{"key":"e_1_3_5_44_1","unstructured":"Dzhuninski. Home. [Internet]. ncpr.bg. 2018. https:\/\/ncpr.bg\/en\/."},{"key":"e_1_3_5_45_1","unstructured":"HALMED. HALMED - Agencija za lijekove i medicinske proizvode [Internet]. HALMED - Agencija za lijekove i medicinske proizvode. 2025. https:\/\/www.halmed.hr\/"},{"key":"e_1_3_5_46_1","unstructured":"S\u00daKL. \u2013 Ofici\u00e1ln\u00ed str\u00e1nky St\u00e1tn\u00edho \u00fastavu pro kontrolu l\u00e9\u010div. 2025. https:\/\/sukl.gov.cz\/."},{"key":"e_1_3_5_47_1","unstructured":"Etusivu. L\u00e4\u00e4kkeiden hintalautakunta. 2025. https:\/\/www.hila.fi\/."},{"key":"e_1_3_5_48_1","unstructured":"ameli. the online health insurance site | ameli.fr | Insured [Internet]. [cited 2025 Sept 1]. Available from: https:\/\/www.ameli.fr\/assure."},{"key":"e_1_3_5_49_1","unstructured":"Customer Center - LAUER-FISCHER GmbH F\u00fcrth. 2025. https:\/\/portal.cgmlauer.cgm.com\/LF\/Seiten\/Verwaltung\/Kundencenter\/1.aspx."},{"key":"e_1_3_5_50_1","unstructured":"\u03a5\u03c0\u03bf\u03c5\u03c1\u03b3\u03b5\u03af\u03bf \u03a5\u03b3\u03b5\u03af\u03b1\u03c2. \u03a5\u03c0\u03bf\u03c5\u03c1\u03b3\u03b5\u03af\u03bf \u03a5\u03b3\u03b5\u03af\u03b1\u03c2. 2025. https:\/\/www.moh.gov.gr\/."},{"key":"e_1_3_5_51_1","unstructured":"Tartalmak. [Internet]. NEAK. 2025. https:\/\/www.neak.gov.hu\/."},{"key":"e_1_3_5_52_1","unstructured":"Gazzetta Ufficiale. 2025. https:\/\/www.gazzettaufficiale.it\/."},{"key":"e_1_3_5_53_1","unstructured":"S\u0101kumlapa. | Nacion\u0101lais vesel\u012bbas dienests. 2025. https:\/\/www.vmnvd.gov.lv\/lv."},{"key":"e_1_3_5_54_1","unstructured":"Prad\u017eia. Valstybin\u0117 ligoni\u0173 kasa prie Sveikatos apsaugos ministerijos [Internet]. [cited 2025 Sept 1]. Available from: https:\/\/ligoniukasa.lrv.lt\/lt\/."},{"key":"e_1_3_5_55_1","unstructured":"Assur\u00e9. 2025 http:\/\/cns.public.lu\/fr\/assure.html."},{"key":"e_1_3_5_56_1","unstructured":"Forside. 2025. https:\/\/www.dmp.no\/."},{"key":"e_1_3_5_57_1","unstructured":"Portal Gov.pl. Gov.pl. 2025. https:\/\/www.gov.pl."},{"key":"e_1_3_5_58_1","unstructured":"User S. AFIE. 2025. https:\/\/www.afiethica.ro\/."},{"key":"e_1_3_5_59_1","unstructured":"Ministerstvo zdravotn\u00edctva Slovenskej republiky. 2025. https:\/\/www.health.gov.sk\/Titulka."},{"key":"e_1_3_5_60_1","unstructured":"JAZMP. \u2013 Javna agencija Republike Slovenije za zdravila in medicinske pripomo\u010dke. 2025. https:\/\/www.jazmp.si\/."},{"key":"e_1_3_5_61_1","unstructured":"Vademecum.es. - Your source of pharmacological knowledge. 2025. https:\/\/www.vademecum.es\/."},{"key":"e_1_3_5_62_1","unstructured":"Tandv\u00e5rds-L\u00e4kemedelf\u00f6rm\u00e5nsverket. Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket TLV. 2025. https:\/\/www.tlv.se."},{"key":"e_1_3_5_63_1","unstructured":"Specialty List (SL) - Overview. 2025. https:\/\/www.spezialitaetenliste.ch\/."},{"key":"e_1_3_5_64_1","unstructured":"British National Formulary. NICE. 2025. https:\/\/www.nice.org.uk\/bnf-uk-only"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin22.489"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-018-0610-z"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pulmoe.2020.03.001"},{"key":"e_1_3_5_68_1","unstructured":"Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain. | Clinical Drug Investigation. 2025. https:\/\/link.springer.com\/article\/10.1007\/s40261-016-0402-2"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.3109\/02770903.2012.717659"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2025.2558450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:46:07Z","timestamp":1766400367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2025.2558450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/13696998.2025.2558450"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2025.2558450","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-08-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}